A Study of the Effectiveness of Virtual Reality Relaxation Combined With Patient-Controlled Analgesia (PCA) Morphine for Those Undergoing Burn Dressing Changes
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Bayside Health.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Bayside Health
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00163917
First received: September 12, 2005
Last updated: March 14, 2007
Last verified: September 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate whether a sub-population of patients with burn injuries needing dressing changes respond to virtual reality (VR) utilising relaxation themes with improved pain and anxiety scores, when added to PCA morphine and background analgesic therapy.
| Condition | Intervention |
|---|---|
|
Anxiety Pain |
Device: Virtual reality relaxation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Predicting the Effectiveness of Virtual Reality Relaxation on Pain and Anxiety When Added to PCA Morphine in a Population of Burn Patients Having Dressing Changes |
Resource links provided by NLM:
Further study details as provided by Bayside Health:
Primary Outcome Measures:
- Association between hypnotic susceptibility and pain scores
- Association between hypnotic susceptibility and anxiety scores
Secondary Outcome Measures:
- Measurement of pain by visual analogue scale (VAS)
- Measurement of anxiety by Burns Specific Anxiety Rating by VAS
- Rating of hypnotic susceptibility and morphine use
- Satisfaction rating
- Morphine use
- Incidence of side effects relating to morphine and VR
| Estimated Enrollment: | 90 |
| Study Start Date: | September 2004 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Burn injury
- Scheduled for painful dressing changes
- Conscious
- Comprehension of PCA and virtual reality device
- Comprehension of the English language
Exclusion Criteria:
- Patient refusal
- Psychotic disease
- Paranoid disease
- Unstable dissociative disorder
- Borderline personality disorder
- Phobias relevant to water/drowning
- Epilepsy/propensity to fitting
- Morphine allergy
- Acute brain syndrome
- Chronic brain syndrome
- Physically unable to administer PCA
- Severe burns involving the head
- Visual impairment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00163917
Contacts
| Contact: Alex Konstantatos, MBBS, FANZCA | 03 92763176 ext 3757 | a.konstantatos@alfred.org.au |
| Contact: Margaret E Angliss, BN | 03 92763176 ext 3757 | m.angliss@alfred.org.au |
Locations
| Australia, Victoria | |
| The Alfred Hospital | Recruiting |
| Melbourne, Victoria, Australia, 3181 | |
| Contact: Alex Konstantatos, MBBS 03 92763176 ext 3757 a.konstantatos@alfred.org.au | |
| Principal Investigator: Alex Konstantatos, MBBS | |
Sponsors and Collaborators
Bayside Health
Investigators
| Principal Investigator: | Alex Konstantatos, MBBS | The Alfred Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00163917 History of Changes |
| Other Study ID Numbers: | 107/ 04 |
| Study First Received: | September 12, 2005 |
| Last Updated: | March 14, 2007 |
| Health Authority: | Australia: National Health and Medical Research Council |
Keywords provided by Bayside Health:
|
Hypnosis Analgesia |
Additional relevant MeSH terms:
|
Anxiety Disorders Mental Disorders Morphine Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotics |
ClinicalTrials.gov processed this record on May 16, 2013